ATE103291T1 - Spezifische liganden fuer oestrogen- und progestagen-steroidhomonrezeptoren, deren verwendung und synthesezwischenprodukte. - Google Patents
Spezifische liganden fuer oestrogen- und progestagen-steroidhomonrezeptoren, deren verwendung und synthesezwischenprodukte.Info
- Publication number
- ATE103291T1 ATE103291T1 AT89402862T AT89402862T ATE103291T1 AT E103291 T1 ATE103291 T1 AT E103291T1 AT 89402862 T AT89402862 T AT 89402862T AT 89402862 T AT89402862 T AT 89402862T AT E103291 T1 ATE103291 T1 AT E103291T1
- Authority
- AT
- Austria
- Prior art keywords
- progestagen
- ligands
- receptors
- steroid
- homon
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 5
- 239000000262 estrogen Substances 0.000 title abstract 2
- 239000000583 progesterone congener Substances 0.000 title abstract 2
- -1 PROGESTAGEN STEROID Chemical class 0.000 title 1
- 239000013067 intermediate product Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 108091008039 hormone receptors Proteins 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000002576 ketones Chemical group 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 108020003113 steroid hormone receptors Proteins 0.000 abstract 1
- 102000005969 steroid hormone receptors Human genes 0.000 abstract 1
- 238000002626 targeted therapy Methods 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8813737A FR2637803B1 (fr) | 1988-10-19 | 1988-10-19 | Ligands specifiques de recepteurs d'hormones steroides estrogenes et progestagenes, application et produits intermediaires de synthese |
| EP89402862A EP0365421B1 (de) | 1988-10-19 | 1989-10-17 | Spezifische Liganden für Östrogen- und Progestagen-Steroidhomonrezeptoren, deren Verwendung und Synthesezwischenprodukte |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE103291T1 true ATE103291T1 (de) | 1994-04-15 |
Family
ID=9371153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89402862T ATE103291T1 (de) | 1988-10-19 | 1989-10-17 | Spezifische liganden fuer oestrogen- und progestagen-steroidhomonrezeptoren, deren verwendung und synthesezwischenprodukte. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5002753A (de) |
| EP (1) | EP0365421B1 (de) |
| JP (1) | JP2779011B2 (de) |
| AT (1) | ATE103291T1 (de) |
| CA (1) | CA2000979C (de) |
| DE (1) | DE68914087T2 (de) |
| FR (1) | FR2637803B1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2613937B1 (fr) * | 1987-04-17 | 1989-07-21 | Ire Celltarg Sa | Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer |
| CN1041829C (zh) * | 1993-06-28 | 1999-01-27 | 中国人民军事医学科学院放射医学研究所 | 17α-乙炔雌三醇-3-环戊醚的制备方法 |
| US5427766A (en) * | 1993-11-15 | 1995-06-27 | The Dow Chemical Company | Radiolabeled steroids for use in radiochemical-guided surgery |
| US5922699A (en) * | 1996-06-07 | 1999-07-13 | Pherin Corporation | 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function |
| JP2010531638A (ja) * | 2007-06-12 | 2010-09-30 | ケース ウエスタン リザーブ ユニバーシティ | 標的化された細胞死 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7405626A (nl) * | 1974-04-26 | 1975-10-28 | Akzo Nv | Nieuwe 11-gesubstitueerde steroiden van de oestraanreeks. |
| JPS6051808A (ja) * | 1983-08-31 | 1985-03-23 | Sumitomo Electric Ind Ltd | 光フアイバユニツト入り架空地線の接続部 |
| DE3337179A1 (de) * | 1983-10-10 | 1985-05-23 | Schering AG, 1000 Berlin und 4709 Bergkamen | Estran- und androstan-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende praeparate |
| ATE37429T1 (de) * | 1984-07-20 | 1988-10-15 | Tol O Matic Inc | Stellglied fuer drehbewegungen. |
| DE3427795A1 (de) * | 1984-07-25 | 1986-02-06 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 17(alpha)-halogenvinyl-estran-derivate, ihre herstellung und verwendung in der medizin |
| FR2613937B1 (fr) * | 1987-04-17 | 1989-07-21 | Ire Celltarg Sa | Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer |
-
1988
- 1988-10-19 FR FR8813737A patent/FR2637803B1/fr not_active Expired - Fee Related
-
1989
- 1989-10-17 EP EP89402862A patent/EP0365421B1/de not_active Expired - Lifetime
- 1989-10-17 AT AT89402862T patent/ATE103291T1/de active
- 1989-10-17 DE DE68914087T patent/DE68914087T2/de not_active Expired - Lifetime
- 1989-10-18 CA CA002000979A patent/CA2000979C/fr not_active Expired - Lifetime
- 1989-10-18 US US07/423,141 patent/US5002753A/en not_active Expired - Lifetime
- 1989-10-19 JP JP1272738A patent/JP2779011B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2637803B1 (fr) | 1993-07-09 |
| JPH02174794A (ja) | 1990-07-06 |
| CA2000979A1 (fr) | 1990-04-19 |
| DE68914087T2 (de) | 1994-09-08 |
| JP2779011B2 (ja) | 1998-07-23 |
| CA2000979C (fr) | 2000-06-13 |
| EP0365421A1 (de) | 1990-04-25 |
| FR2637803A1 (fr) | 1990-04-20 |
| US5002753A (en) | 1991-03-26 |
| DE68914087D1 (de) | 1994-04-28 |
| EP0365421B1 (de) | 1994-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miller et al. | Oestradiol synthesis from C19 steroids by human breast cancers | |
| Fisher et al. | Cancer of the breast: size of neoplasm and prognosis | |
| DE69126816T2 (de) | Metallkomplexe, die Addukte von Säure und Dioximliganden enthalten, zur Markierung von Proteinen und anderen Amin enthaltenden Verbindungen | |
| DE3687736D1 (de) | Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung. | |
| Hanson et al. | Preparation and evaluation of 17α-[125I] iodovinyl-11β-methoxyestradiol as a highly selective radioligand for tissues containing estrogen receptors: concise communication | |
| AU6198086A (en) | Agents for use in tumour diagnosis, imaging, localization or treatment | |
| DE68914087D1 (de) | Spezifische Liganden für Östrogen- und Progestagen-Steroidhomonrezeptoren, deren Verwendung und Synthesezwischenprodukte. | |
| Bigott et al. | Design and synthesis of functionalized cyclopentadienyl tricarbonylmetal complexes for technetium-94m PET imaging of estrogen receptors | |
| Ramesh et al. | Linkage Effects on Binding Affinity and Activation of GPR30 and Estrogen Receptors ERα/β with Tridentate Pyridin-2-yl Hydrazine Tricarbonyl− Re/99mTc (I) Chelates | |
| FR2613937B1 (fr) | Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer | |
| ATE28752T1 (de) | 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate. | |
| Garin et al. | Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs | |
| Hunter et al. | Single isomer technetium-99m tamoxifen conjugates | |
| Sykes et al. | Direct labeling of monoclonal antibodies with technetium-99m by photoactivation | |
| LAMB et al. | Sensitivity to fluorescent (blue-green) light | |
| Adjogatse et al. | 170 Long term outcomes of the FiGaRO trial: 18F-FDG-PET in Guided Dose-Painting with Intensity Modulated Radiotherapy in Oropharyngeal Tumours | |
| Ash et al. | Biliary and faecal excretion of misonidazole in man | |
| DE69414129D1 (de) | Biphenyl jodierte derivate und ihre verwendung als diagnostikum | |
| Grimes | Progestins, breast cancer, and the limitations of epidemiology | |
| Johnson et al. | A testing system for drug-induced peripheral neuropathy in mice | |
| Delclos et al. | Can the fletcher gamma ray colpostat system be extrapolated to other systems? | |
| Hainfeld et al. | Derivatized gold clusters and antibody-gold cluster conjugates | |
| Reinstein et al. | Portal film duplication using instant photography | |
| Gopal et al. | Feasibility studies of radiation sterilization of some pharmaceutical products | |
| Quinn et al. | Management of advanced gynecologic malignancies with dominant pelvic presentations |